Systematic Review and Meta-analysis of Vagus Nerve Stimulation in the Treatment of Heart Failure

  • Cristina FURNICA Forensic Medicine Institute & “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
  • Raluca Ozana CHISTOL Prof. Dr. George I.M. Georgescu” Cardiovascular Diseases Institute, Iasi, Romania
  • Mihaela GRECU Prof. Dr. George I.M. Georgescu” Cardiovascular Diseases Institute, Iasi, Romania
  • Mihaela TOMAZIU-TODOSIA Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
  • Grigore TINICA Prof. Dr. George I.M. Georgescu” Cardiovascular Diseases Institute & “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
Keywords: atrial fibrillation, heart failure, vagus nerve stimulation, NYHA class

Abstract

The vagus nerve, the longest cranial nerve, mixed, with both motor and sensitive components, innervates the structures derived from the last two pharyngeal arches and constitutes the main efference of the cranial parasympathetic system, presenting the widest distribution in the human body. Vagus nerve dysfunction is encountered in several cardiac diseases including atrial fibrillation (AFib) and heart failure. Vagus nerve stimulation (VNS) may slow or cancel pathophysiological processes involved in heart failure development. The aim of the current study was to perform a meta-analysis of the available data obtained in a clinical setting for VNS in heart failure patients in order to establish a potential benefit in terms of cardiac function. The authors performed a systematic review and meta-analysis of available data published between January 2010 - April 2017 by searching the Medline database using “vagus nerve stimulation” and “heart failure” as keywords. From 116 identified studies, only 4 met the inclusion criteria after abstract analysis. The four identified studies (2 randomized, 2 non-randomized) evaluated the effect of VNS in patients ³18 years-old with NYHA functional class II-III heart failure due to various causes and reduced left ventricular ejection fraction. The two randomized trials failed to demonstrate a significant improvement of mortality rate, functional remodelling or functional capacity in symptomatic heart failure patients compared to the two non-randomized trials that displayed promising results on small and biased study groups. Their observed benefits in quality of life have to be interpreted with caution given the subjective nature and lack patient blindness. In conclusion, prior to new clinical studies, the specific site, intensity and duration of adequate stimulation should be identified together with a method of isolating the efferent vagal fibres in order to avoid cross-stimulation and side-effects.

References

[1] Abraham WT, Zile MR, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail. 2015; 3:487-96.
[2] Binder DK, Sonne DC, Fischbein NJ. Cranial nerves: anatomy, pathology, imaging. New York:Thieme Ed. 2010.
[3] De Ferrari GM, Crijns HJ, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011; 32:847-55.
[4] Dicarlo L, Libbus I, Amurthur B, Kenknight BH, Anand IS. Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: the ANTHEM-HF study. J Card Fail. 2013; 19(9):655-60.
[5] Furnica C, Varlam H, Minea R, Antohe DSt. Peripheral nervous system: cranial nerves. Iasi: Ed. Junimea. 2011.
[6] Gold MR, Van Veldhuisen DJ, Hauptman PJ, Borggrefe M, Kubo SH, Lieberman RA, Milasinovic G, Berman BJ, Djordjevic S, Neelagaru S, Schwartz PJ, Starling RC, Mann DL. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016; 68(2):149-58.
[7] Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, Starling RC, Mann DL. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012; 163(6):954-962.e1.
[8] Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004; 109:120–124.
[9] Premchand RK, Sharma K, Mittal S, Monteiro R, Dixit S, Libbus I, DiCarlo LA, Ardell JL, Rector TS, Amurthur B, KenKnight BH, Anand IS. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail. 2014; 20(11):808-16.
[10] Schachter SC. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology. 2002;59:S15–S20.
[11] Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008; 10:884–891.
[12] Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med. 2007; 356:1604–1607.
[13] Tinica G, Furnica C eds. Cordul. Anatomie clinica si chirurgicala. Iasi: Editura Universitatii „Alexandru Ioan Cuza”. 2015.
[14] Torre-Amione G, Alo K, Estep JD. Spinal cord stimulation is safe and feasible in patients with advanced heart failure: early clinical experience. Eur J Heart Fail. 2014; 16:788-795.
[15] Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res. 1991; 68:1471–1481.
[16] Yeh YH, Lemola K, Nattel S. Vagal atrial fibrillation. Acta Cardiol Sin 2007; 23:1-12.
[17] Zannad F, De Ferrari GM, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015; 36(7):425-433.
Published
2017-08-18
How to Cite
FURNICA, C., CHISTOL, R., GRECU, M., TOMAZIU-TODOSIA, M., & TINICA, G. (2017). Systematic Review and Meta-analysis of Vagus Nerve Stimulation in the Treatment of Heart Failure. LUMEN Proceedings, 1, 243-256. https://doi.org/10.18662/lumproc.rsacvp2017.23

Most read articles by the same author(s)